Cargando…
High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study
Australia was one of the first countries with unrestricted access to government subsidized direct‐acting antiviral (DAA) therapy for adults with chronic hepatitis C virus. This study assessed real‐world DAA treatment outcomes across a diverse range of Australian clinical services and evaluated facto...
Autores principales: | Yee, Jasmine, Carson, Joanne M., Hajarizadeh, Behzad, Hanson, Joshua, O’Beirne, James, Iser, David, Read, Phillip, Balcomb, Anne, Doyle, Joseph S., Davies, Jane, Martinello, Marianne, Marks, Philiipa, Dore, Gregory J., Matthews, Gail V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870316/ https://www.ncbi.nlm.nih.gov/pubmed/34729957 http://dx.doi.org/10.1002/hep4.1826 |
Ejemplares similares
-
Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort
por: Carson, Joanne M., et al.
Publicado: (2022) -
Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021
por: Carson, Joanne, et al.
Publicado: (2023) -
Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000‐2014)
por: Waziry, Reem, et al.
Publicado: (2017) -
Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia
por: Yousafzai, Mohammad T., et al.
Publicado: (2022) -
Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial
por: Grebely, Jason, et al.
Publicado: (2020)